Herriot Tabuteau, Axsome CEO (Photo by Owen Hoffmann/Patrick McMullan via Getty Images)
February 27, 2023 10:10 AM EST
R&D
FDA+

Ax­some says FDA wants more da­ta for Alzheimer’s ag­i­ta­tion la­bel ex­pan­sion, but read­out to come soon­er 

Kyle LaHucik

Senior Reporter

Ax­some Ther­a­peu­tics said the FDA wants safe­ty in­for­ma­tion from the biotech’s third Phase III study of its drug can­di­date for Alzheimer …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

Jim Wilson's Gem­ma­Bio rais­es $34M to com­mer­cial­ize gene ther­a­pies for rare dis­eases

A service from the Financial Times